Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Investor Day (October 2022)
8 slides from Celon Pharma Sa's investor day presentation, October 2022
Slide 1: Metabolic Disorders
Metabolic Disorders Katarzyna Bazydło-Guzenda Clinical Development Leader Celon Pharma Investor Day 2022
Slide 2: Metabolic Projects
Metabolic Projects
Slide 3: CPL'280 – Clinical Development: Type 2 Diabetes
CPL’280 – Clinical Development Type 2 Diabetes PHASE 1 PHASE 2a PHASE 2b 01GPR2019 02GPR2021 (T2D) 68 healthy volunteers 80 patients with T2D 150 patients with T2D Safety/PK/Food effect 2 weeks vs placebo 8 weeks vs placebo Single ascending dose (SAD) and Efficacy/Safety/PK Efficacy/Safety/PK Multip
Slide 4: CPL'280 – Clinical Development: Diabetic Neuropathy
CPL’280 – Clinical Development Type 2 Diabetes PHASE 1 PHASE 2a PHASE 2b 01GPR2019 02GPR2021 (T2D) 68 healthy volunteers 80 patients with T2D 150 patients with T2D Safety/PK/Food effect 2 weeks vs placebo 8 weeks vs placebo Single ascending dose (SAD) and Efficacy/Safety/PK Efficacy/Safety/PK Multip
Slide 5: CPL'280 - T2D study status
CPL’280 - T2D study status ” A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics After 2-weeks Administration of CPL207280 (GPR40 Agonist) in Subjects With Type 2 Diabetes .” NCT05248776 Study status Study participants Patie
Slide 6: CPL'280 - DN study status
CPL’280 - DN study status IND IND submission „green light” Q1 2023 Q1/Q2 2023 Q2 2023 – Q1 2024 PHASE 2 03GPR2022 60 patients z DN 6 weeks vs placebo IND Efficacy/Safety/PK
Slide 7: CPL'280 – scientific articles
CPL’280 – scientific articles
Slide 8: Metabolic Disorders
Metabolic Disorders Katarzyna Bazydło-Guzenda Clinical Development Leader katarzyna.bazydlo@celonpharma.com Celon Pharma Investor Day 2022